Analysis: Cholesterol-Drug Setback Key To Takeda Pipeline (Japan)
This article was originally published in PharmAsia News
Executive Summary
The setback of Takeda Pharmaceutical's entry into the anti-cholesterol drug market is having a financial impact on Japan's leading drug maker. The company had viewed its TAK-475 as the most promising drug in its pipeline, but the U.S. FDA said it needed more clinical tests before it could approve the drug. Takeda faces 2010 expiration of patents on several of its flagship drugs and needs to come up with substitutes if it is to regain investor confidence. (Click here for more - may require a subscription